FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283275870> ?p ?o ?g. }

• W4283275870 endingPage "e062907" @default.
• W4283275870 startingPage "e062907" @default.
• W4283275870 abstract "Introduction Malignant peritoneal mesothelioma (MPM) is a rare, aggressive tumour arising primarily from the peritoneum. The only potentially curative treatment is cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). However, the majority of patients are not eligible to undergo this treatment. The benefit of systemic treatment for these patients is limited at the cost of considerable morbidity. Hence, there is a need for appropriate palliative treatment options for patients with MPM. As MPM rarely disseminates outside the abdominal cavity, these patients might benefit from local treatment. A higher, more effective dose of chemotherapy can directly be delivered at the site of the disease. Systemic uptake will be limited, likely resulting in less toxicity. The aim of the INTERACT MESO trial is to determine the maximum tolerable dose of intraperitoneal paclitaxel monotherapy in patients with MPM. Secondary endpoints are to assess safety and toxicity, feasibility and the pharmacokinetic profile of this treatment. Methods and analysis The INTERACT MESO trial is a prospective, open-label, single-centre, phase I study with a classic three-plus-three dose escalation design. The study population consists of adult patients with primary MPM, without extra-abdominal disease, who are not eligible to undergo CRS-HIPEC. According to standard of care work-up for CRS-HIPEC, patients will undergo diagnostic laparoscopy to determine the feasibility of CRS-HIPEC. In case CRS-HIPEC is not considered feasible, a peritoneal port-a-cath (PAC) system will be placed. Through this PAC, 8–16 weekly cycles of intraperitoneal chemotherapy will be administered. Ethics and dissemination The Central Committee on Research Involving Human Subjects (CCMO, The Hague, The Netherlands) and the Medical Research Ethics Committee (METC, Rotterdam, The Netherlands) have granted permission to carry out this study protocol. The results of this trial will be submitted for publication in a peer-reviewed scientific journal. Trial registration number NL9718. EudraCT: 2021-003637-11." @default.
• W4283275870 created "2022-06-23" @default.
• W4283275870 creator A5003594769 @default.
• W4283275870 creator A5008685422 @default.
• W4283275870 creator A5012937808 @default.
• W4283275870 creator A5013432555 @default.
• W4283275870 creator A5021833630 @default.
• W4283275870 creator A5033102166 @default.
• W4283275870 creator A5048678810 @default.
• W4283275870 creator A5055194493 @default.
• W4283275870 creator A5065885053 @default.
• W4283275870 creator A5074174053 @default.
• W4283275870 date "2022-06-01" @default.
• W4283275870 modified "2023-09-26" @default.
• W4283275870 title "Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study—INTERACT MESO" @default.
• W4283275870 cites W1871865048 @default.
• W4283275870 cites W1944392621 @default.
• W4283275870 cites W1992718174 @default.
• W4283275870 cites W2036311740 @default.
• W4283275870 cites W2057831335 @default.
• W4283275870 cites W2060760531 @default.
• W4283275870 cites W2066343477 @default.
• W4283275870 cites W2142114138 @default.
• W4283275870 cites W2150737595 @default.
• W4283275870 cites W2171811563 @default.
• W4283275870 cites W2580822306 @default.
• W4283275870 cites W2891660573 @default.
• W4283275870 cites W2945590213 @default.
• W4283275870 cites W2981177819 @default.
• W4283275870 cites W2992565837 @default.
• W4283275870 cites W3001175095 @default.
• W4283275870 cites W3122627530 @default.
• W4283275870 doi "https://doi.org/10.1136/bmjopen-2022-062907" @default.
• W4283275870 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35732399" @default.
• W4283275870 hasPublicationYear "2022" @default.
• W4283275870 type Work @default.
• W4283275870 citedByCount "2" @default.
• W4283275870 countsByYear W42832758702023 @default.
• W4283275870 crossrefType "journal-article" @default.
• W4283275870 hasAuthorship W4283275870A5003594769 @default.
• W4283275870 hasAuthorship W4283275870A5008685422 @default.
• W4283275870 hasAuthorship W4283275870A5012937808 @default.
• W4283275870 hasAuthorship W4283275870A5013432555 @default.
• W4283275870 hasAuthorship W4283275870A5021833630 @default.
• W4283275870 hasAuthorship W4283275870A5033102166 @default.
• W4283275870 hasAuthorship W4283275870A5048678810 @default.
• W4283275870 hasAuthorship W4283275870A5055194493 @default.
• W4283275870 hasAuthorship W4283275870A5065885053 @default.
• W4283275870 hasAuthorship W4283275870A5074174053 @default.
• W4283275870 hasBestOaLocation W42832758701 @default.
• W4283275870 hasConcept C121608353 @default.
• W4283275870 hasConcept C126322002 @default.
• W4283275870 hasConcept C141071460 @default.
• W4283275870 hasConcept C142724271 @default.
• W4283275870 hasConcept C143998085 @default.
• W4283275870 hasConcept C203092338 @default.
• W4283275870 hasConcept C2776694085 @default.
• W4283275870 hasConcept C2777407522 @default.
• W4283275870 hasConcept C2778995398 @default.
• W4283275870 hasConcept C2779458272 @default.
• W4283275870 hasConcept C2780427987 @default.
• W4283275870 hasConcept C2908647359 @default.
• W4283275870 hasConcept C2994223192 @default.
• W4283275870 hasConcept C535046627 @default.
• W4283275870 hasConcept C71924100 @default.
• W4283275870 hasConcept C99454951 @default.
• W4283275870 hasConceptScore W4283275870C121608353 @default.
• W4283275870 hasConceptScore W4283275870C126322002 @default.
• W4283275870 hasConceptScore W4283275870C141071460 @default.
• W4283275870 hasConceptScore W4283275870C142724271 @default.
• W4283275870 hasConceptScore W4283275870C143998085 @default.
• W4283275870 hasConceptScore W4283275870C203092338 @default.
• W4283275870 hasConceptScore W4283275870C2776694085 @default.
• W4283275870 hasConceptScore W4283275870C2777407522 @default.
• W4283275870 hasConceptScore W4283275870C2778995398 @default.
• W4283275870 hasConceptScore W4283275870C2779458272 @default.
• W4283275870 hasConceptScore W4283275870C2780427987 @default.
• W4283275870 hasConceptScore W4283275870C2908647359 @default.
• W4283275870 hasConceptScore W4283275870C2994223192 @default.
• W4283275870 hasConceptScore W4283275870C535046627 @default.
• W4283275870 hasConceptScore W4283275870C71924100 @default.
• W4283275870 hasConceptScore W4283275870C99454951 @default.
• W4283275870 hasIssue "6" @default.
• W4283275870 hasLocation W42832758701 @default.
• W4283275870 hasLocation W42832758702 @default.
• W4283275870 hasLocation W42832758703 @default.
• W4283275870 hasLocation W42832758704 @default.
• W4283275870 hasLocation W42832758705 @default.
• W4283275870 hasOpenAccess W4283275870 @default.
• W4283275870 hasPrimaryLocation W42832758701 @default.
• W4283275870 hasRelatedWork W2044916618 @default.
• W4283275870 hasRelatedWork W2079987405 @default.
• W4283275870 hasRelatedWork W2155428653 @default.
• W4283275870 hasRelatedWork W2323973977 @default.
• W4283275870 hasRelatedWork W2795556747 @default.
• W4283275870 hasRelatedWork W2891660573 @default.
• W4283275870 hasRelatedWork W2914544320 @default.
• W4283275870 hasRelatedWork W2997728035 @default.

• next